45 results
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
by physicians, patients, third-party payors and others in the medical community necessary for commercial success and the market opportunity for APHEXDA … in the medical community necessary for commercial success and the market opportunity for APHEXDA or any other therapeutic candidate may be smaller than our
6-K
EX-99
BLRX
Bioline Rx Ltd
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
FDA approvals of two gene therapies for sickle cell disease in the U.S. is an exciting development for the sickle cell community, and we are eager
6-K
EX-99
BLRX
Bioline Rx Ltd
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
to accelerate availability to patients and maximize value through
independent commercialization
to well-defined U.S. transplant center community … and targeted sales force to support outreach to this well-defined community.
“We are excited to announce our plan to commercialize Motixafortide, now known
6-K
EX-99
uz8zsbw7
27 Mar 19
BioLineRx Announces Successful Engraftment Data
7:01am
6-K
EX-99
88strpvkd1i5fvxx1i0o
7 Aug 18
BioLineRx Announces Positive Results of Lead-in Period
7:00am
20-F/A
uomru3nzvcl4
23 Mar 15
Annual report (foreign) (amended)
12:00am
424B5
0jdmr
6 Mar 15
Prospectus supplement for primary offering
12:00am